Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
AstraZeneca ( (GB:AZN) ) has shared an update.
AstraZeneca, in collaboration with Daiichi Sankyo, has received its first US approval for Datroway (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate, for treating previously treated metastatic HR-positive, HER2-negative breast cancer. The approval, based on the TROPION-Breast01 Phase III trial results, marks a significant milestone in offering a new treatment option, reducing disease progression or death risk by 37% compared to chemotherapy, thereby advancing AstraZeneca’s goal to provide innovative cancer therapies.
More about AstraZeneca
AstraZeneca is a global pharmaceutical company focused on the development and commercialization of medicines across several therapeutic areas, including oncology, cardiovascular, renal, and metabolism, and respiratory. It has a comprehensive portfolio in breast cancer with both approved and investigational compounds, aiming to redefine the clinical approach to breast cancer treatment.
YTD Price Performance: 4.49%
Average Trading Volume: 2,758,233
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £169.6B
See more insights into AZN stock on TipRanks’ Stock Analysis page.
